-5%
Xenobese 120 is indicated for the treatment of obesity.
- Xenobese 120 is used in the treatment of obesity by blocking the absorption of fats from the small intestines and stomach.
- Orlistat is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) >30 kg/m² and overweight patients (BMI >28 kg/m²) with associated risk factors such as type II diabetes, hyperlipidemia, and hypertension. Treatment with Adiponil should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.
- Obese adolescents should be treated with Adiponil only if an adequate reduction of body weight cannot be achieved by employing diet & increased physical activity. Treatment with Adiponil should be considered, in particular, if complications of obesity are present.
- It should be taken along with food as per the prescribed dose and duration.
- Common side effects include abdominal pain, the presence of fat in the stool, diarrhea, etc.
- Pregnant and breastfeeding women should use it only with a valid prescription.
- It should not be considered a long-term treatment without a doctor’s advice.
- The tolerability and efficacy of Orlistat have not been studied in elderly patients or patients with hepatic and/or renal impairments.